In this Annual Review Issue of The Journal of Pathology, we present 15 invited reviews on topical aspects of pathology, ranging from the impacts of the microbiome in human disease through mechanisms of cell death and autophagy to recent advances in immunity and the uses of genomics for understanding, classifying and treating human cancers. Each of the reviews is authored by experts in their fields and our intention is to provide comprehensive updates in specific areas of pathology in which there has been considerable recent progress.
Introduction
The Annual Review Issue has become a traditional part of The Journal of Pathology, with this being the 21st such issue. Now that we have 'come of age', this year's collection of reviews sees a break from the previous tradition of having themed issues, such as 'The Molecular Pathology of Cancer' in 2018 (https://onlinelibrary .wiley.com/toc/10969896/2018/244/5) and 'The Genetics of Disease' in 2017 (https://onlinelibrary.wiley.com/ toc/10969896/2017/241/2). Instead, we have broadened the remit to cover individual areas in which we feel there have been significant advances in recent years. In this way, we hope that we can be more nimble and adaptable and thereby bring important developments in the study of human disease to attention, regardless of their specific sub-speciality. However, we continue to maintain our commitment to provide high quality reviews that are in keeping with the mission of the journal -understanding disease. In addition, we continue to make all articles in our Annual Review Issues Free Access to enhance their usefulness to pathologists and scientists across the world.
CS Herrington et al
from the UK, Australia and Mexico joining forces to discuss the current thinking on melanoma subtypes, paying specific attention to the impact of genomic profiling for providing prognostic biomarkers and new therapeutic opportunities [1] . Our second cancer-related contribution, from Sunil Lakhani and colleagues in Brisbane, provides an updated view on the diagnostic classification of breast cancer. The review discusses the latest information on clinical trials and the use of gene-based diagnostic panels, which are now showing value for treatment decisions. The recent developments in immuno-oncology and emerging targeted therapies are also discussed [2] . A review from researchers in Sweden and Canada brings together the recent findings of molecularly distinct clusters that explain the clinical heterogeneity of urothelial carcinoma [3] . These cell-based subtypes reflect intrinsic urothelial cell-type diferentiation pathways, including basal and luminal phenotypes, similar to the more widely accepted classification of breast cancers. The authors highlight the potential value of urothelial carcinoma subtyping. They also propose a simple immunohistochemistry-based cell type profiling method that could be adopted into routine pathology practice, for ongoing research and clinical trials, and for improved diagnosis [3] . The final review in this cancer-related set of papers deals with inherited susceptibility to colorectal carcinoma [4] . Laura Valle and colleagues discuss the subdivision of colorectal carcinoma predisposition syndromes into polyposis and non-polyposis entities and present strategies for improving the main classification systems. They also provide an update on the identification of moderate-pentrance genes and their impact on genetic testing and counselling, together with an in-depth disscussion of the challenges in classifying genetic variants of unknown significance. Finally, their review highlights approaches for integrating chemopreventive measures and the use of targeted agents and immunotherapy [4] .
Malignancy, immunity and microenvironments
The role of the immune system in the formation and treatment of malignancies is becoming increasingly clear, and the success of immune checkpoint inhibitors is driving this field forward in attempts to harness inherent anti-tumour immune responses for therapeutic purposes. In this Issue, we have three reviews that deal with very different aspects of this broad field. First, Daniela Quail and colleagues review the role of the innate immune system in lung malignancies, including metastasis to the lung [5] . They summarise the interactions of tumour cells with recruited and tissue-resident immune cells, including roles for the lung microbiome, tumour-derived exosomes, neutrophil extracellular traps, myeloid-derived suppressor cells and the intersections between innate and adaptive immunity. They also provide an update on ongoing phase I, II and III clinical trials targeting different elements of the lung tumour environment [5] . The review from Alan Melcher and colleagues [6] deals with the dual effects of conventional genotoxic therapies on immune modulation. They discuss the mechanisms involved in the immune response to radiation-induced DNA damage, emphasising the role of induced interferon reponses in both direct and abscopal responses and the paradoxical immunosuppression observed for tumours with chronic interferon signalling prior to treatment. The authors conclude that high quality translational studies of human material will be necessary for an improved understanding of the immunological effects of genotoxic anti-cancer therapy [6] . The third review here deals with the relatively new area of 'molecular pathological epidemiology' (MPE) and is written by pioneers in this field, Shuji Ogino and colleagues [7] . They review the increasing potential for personalised medicine and public health through using 'omics' data in population-based research. In particular, they propose the integration of microbiome data (viruses, bacteria, fungi and parasites) into MPE to inform the complexity of interactions and responses of tumour cells, the microbiome, immune cells and other components of the tumour microenvironment. These studies will not only improve our understanding of the microbiome as a cause of cancer, but also provide informative biomarkers for treatment or prevention of specific conditions [7] .
A separate but related issue is the extracellular matrix (ECM) components of tumour microenvironments and the roles of matrix metalloproteinases (MMPs) in ECM modification. Guy Conlon and Graeme Murray review latest advances in understanding the biophysical properties of the ECM, the importance of matrix stiffness and its modification by MMPs [8] . They highlight advances in understanding the regulation of MMPs and the role of immune cell-derived MMPs. The review provides a framwework for therapeutic targeting of MMPs; recent advances in the development of selective MMP inhibitors are also reviewed.
New and evolving methodologies
The use of 'liquid biopsies' is a current hot topic in cancer research and pathology, acting as a minimally-invasive approach to identify tumour-derived DNA alterations. However, to date, the clinical applications are limited, due partly to an incomplete knowledge of the characterstics of circulating tumour DNA and the accompanying problems with methodologies and data interpretation. The review from Dennis Lo and colleagues in Hong Kong discusses these and other issues, using plasma Epstein-Barr Virus (EBV) as an example [9] . They show how circulating EBV DNA is a useful marker for diagnosis and monitoring of patients with nasopharyngeal carcinoma, and use this as a paradigm to investigate the peculiarites of circulating tumour-derived DNA. Their up-to-date and authoritative review summarises the specific problems encountered
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and how these need to be taken into account and minimised for improved performance and interpretation of these approaches [9] . High throughput technologies such as microarrays and proteomics are well established, but are constantly evolving. In addition, multiplexing methodologies are developing rapidly, as reviewed by James Ziai and colleagues at Genentech based on their experiences [10] . They discuss the basic principles of high multiplexing platforms (>20 targets) that accurately measure protein and RNA -Digital Spatial Profiling, Imaging Mass Cytometry, Multiplex Ion Beam Imaging and MultiOmyx -and how these can provide accurate characterisation of the spatial relationships of tumour constituents and heterogeneity. They also discuss issues such as pre-analytical variability, sampling and specimen quality and emphasise the need for appropriate expertise in data interpretation [10] .
Innate and adaptive immunity in development, health and disease
As mentioned above, immune responses are increasingly recognised as important constituents of many malignancies. In addition, our understanding of immunity in health and disease is increasing rapidly. Sussan Nourshargh has been investigating the roles of neutrophils for many years, including their migration into different compartments of the immune system. In their review, she and Mathieu-Benoit Voisin provide a comprehensive assessment of the role of neutrophils in orchestrating activation/suppression of lymphocytes in homeostasis and chronic inflammation, including autoimmune disorders and cancer. Within this, they discuss the emerging evidence for distinct and diverse neutrophil phenotypes that characterise different pathological conditions. Thus, neutrophils are now known to be crucial for adaptive immunity and are not solely involved in acute innate immunity [11] . The second article in this section, from David Dorward and colleagues, reviews our current understanding of acute respiratory distress syndrome (ARDS), paying particular attention to the role of neutrophils in initiating and propagating the disease, and in its resolution. The review explores the complex inflammatory environment of ARDS, recent advances in understanding neutrophil function and the factors that influence them throughout ARDS, including how this increased understanding provides potential therapeutic targets for this currently untreatable disease [12] . The role of immunity in lung development is the subject of our third review [13] . Philip Hansbro and colleagues first review the five stages of lung embryonic and post-natal development, involving Nkx2.1, fibroblast growth factors, sonic hedgehog and Wnt signalling, amongst others. They then discuss the findings that inflammatory responses in early life affect lung development, with bronchopulmonary dysplasia representing a good example. This leads to a comprehensive review of type 2 immunity in lung development, including alveolar macrophages and group 2 innate lymphoid cells (ILC2s). The authors conclude that type 2 immunity may serve as a novel intervention to promote normal post-natal alveolarisation and prevent chronic respiratory diseases [13] .
Autophagy and regulated necrosis
Necrosis can be defined as the loss of plasma membrane integrity, leading to cell death. There are several morphological forms of necrosis and a number of biochemical pathways that lead to genetically defined types of regulated necrosis. Recent advances are reviewed by Andreas Linkermann and colleagues, highlighting necroptosis, pyroptosis and ferroptosis and the role of necrosis in acute kidney injury, severe inflammatory response syndrome and transplantation, amongst other pathologies. They point out that increased undestanding of these processes is allowing the development of simple assays that will allow detailed invetigations into their roles in disease [14] . In contrast to necrosis, autophagy is a survival mechanism that is induced by many cellular stresses, including cancer therapies. Alexandra Smith and Kay Macleod review multiple aspects of autophagy (and mitophagy) in promoting stemness, dormancy and therapy resistance and how these selective forms of autophagy could be manipulated for therapeutic benefit [15] .
Conclusion
The broad range of reviews included in this Annual Review Issue demonstrates that our understanding of disease, and the application of this understanding to disease diagnosis and patient management, is developing rapidly across a number of fronts. We hope that this collection will be of interest to a wide range of readers.
